Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...